TICKERNERD
Menu
WVEWVEHealthcare · Biotechnology

WVE Stock Forecast: Wave Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$3.09
−1.59% on the day

The 19 Wall Street analysts covering Wave Life Sciences, Inc. hold a median 12-month price target of $15 — +369.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$618.7M
Ticker Nerd rank
14 / 100
Median analyst target
$15
Analysts covering
19
Revenue$2.3M−73.9% y/y
Operating income−$73.8M
Net income−$69.4M
Free cash flow−$54.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.7%
1M
−32.5%
YTD
−81.8%
1Y
−60.8%
From 52W high
−85.5%
From 52W low
0.0%
$3
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WVE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Wave Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
53
Size
50
Revisions
43
Value
40
Accruals
31
Growth
30
Volatility
17
Momentum
14
Issuance
14

Quality (53): The business earns solid, repeatable profits on what it owns.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WVE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WVE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26WVEHigh $42Median $15Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
17 Buy2 Hold0 Sell
Low $10Median $15High $42

The green dot is the last close — the median target sits +369.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
1 Oct 2026Ladenburg ThalmannInitiatesBuy$10
23 Sept 2026JP MorganDowngradeNeutral—
23 Sept 2026JP MorganDowngradeNeutral—
4 Aug 2026MizuhoMaintainsOutperform$27 → $23
4 Aug 2026MizuhoMaintainsOutperform—
31 July 2026B. Riley SecuritiesMaintainsBuy—
31 July 2026B. Riley SecuritiesMaintainsBuy$31 → $22
31 July 2026CitigroupMaintainsBuy$24 → $19
31 July 2026CitigroupMaintainsBuy—
31 July 2026WedbushMaintainsOutperform—
31 July 2026WedbushMaintainsOutperform$15 → $12
20 May 2026Wells FargoMaintainsOverweight$13 → $14
20 May 2026Wells FargoMaintainsOverweight—
19 May 2026HC Wainwright & Co.MaintainsBuy$18 → $13
19 May 2026HC Wainwright & Co.MaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
30 Apr 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026Truist SecuritiesMaintainsBuy—
14 Apr 2026HC Wainwright & Co.MaintainsBuy—
27 Mar 2026B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WVE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

WVE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Wave Life Sciences, Inc. returned −60.8% against +17.5% for the S&P 500, dividends included.

WVE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26WVES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WVE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Wave Life Sciences, Inc. (WVE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.6×

Cheaper than 87% of US stocks

Price / sales
9.5×

Cheaper than 15% of US stocks

Price / book
1.3×

Cheaper than 59% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
−73.9%

Higher than 3% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3248.3%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−67.4%

Higher than 18% of US stocks

Return on assets
−33.6%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Wave Life Sciences, Inc. (WVE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Wave Life Sciences, Inc. has a market value of $618.7M and an enterprise value of $171.7M.

  • Revenue in the twelve months to 30 June 2026: $65.4M. The latest quarter shrank 73.9% year on year.

  • Net income over the same four quarters: −$202.5M, a −309.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.09.

  • Free cash flow in the twelve months to 30 June 2026: −$193.1M.

  • Shares outstanding: 193.3M.

  • Trailing P/E: −2.6×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Wave Life Sciences, Inc. employs 317 people — $206K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

WVE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
WVEWave Life Sciences, Inc.$618.7M
14
OLMAOlema Pharmaceuticals, Inc.$592.7M
26
CLYMClimb Bio, Inc.$589.2M
66
DSGNDesign Therapeutics, Inc.$600.1M
59
ZVRAZevra Therapeutics, Inc.$600.6M
99
PHATPhathom Pharmaceuticals, Inc.$579.4M
82
CRMDCorMedix, Inc.$576.0M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Wave Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WVE news & analysis

Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference

GlobeNewsWire · 13 Oct 2026neutral

Wave Life Sciences announced that CEO Paul Bolno is scheduled to participate in a panel on next-generation RNA therapeutics at Chardan’s 10th Annual Healthcare Conference. The panel is scheduled for October 20, 2026, at 9:45 a.m. ET in New York City.

Why it matters — The appearance gives WVE watchers an opportunity to hear the company’s CEO discuss RNA therapeutics at an industry conference.

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

GlobeNewsWire · 1 Oct 2026positive

Wave Life Sciences announced that, after a meeting with the FDA, it plans to advance WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD), through a single, two-year registrational trial. The trial will include a one-year interim analysis that could support potential accelerated approval based on AATD biomarkers.

Why it matters — FDA feedback supporting a feasible registrational pathway for WVE-006 provides regulatory clarity on a pathway toward potential approval for the RNA-editing program.

Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development

GlobeNewsWire · 30 Sept 2026positive

Wave Life Sciences announced that GSK has selected a siRNA program to transition to GSK for further development. The candidate uses Wave's SpiNA siRNA design and triggers a milestone payment to Wave, with three additional collaboration programs still advancing.

Why it matters — WVE watchers would care because this selection by GSK validates Wave's siRNA platform, brings a milestone payment, and signals continued progress in the collaboration.

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

Zacks Investment Research · 28 Sept 2026positive

Zacks highlights Wave Life Sciences alongside Alnylam, Ionis, and Arcturus as one of four RNA therapeutics companies leading innovation in treatments targeting a range of diseases.

Why it matters — The article positions WVE among the leading RNA therapeutics innovators, raising its profile within the sector for investors tracking the company.

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

GlobeNewsWire · 23 Sept 2026positive

Wave Life Sciences has initiated a Phase 2a combination trial of WVE-007, its GalNAc-siRNA therapy, together with tirzepatide for obesity. Clinical data support 1-2x per year dosing for WVE-007, which induces fat loss without muscle loss, while preclinical data show the combination doubled weight loss compared with a GLP-1 alone.

Why it matters — A WVE watcher would care because this trial expands the therapeutic potential of Wave's GalNAc-siRNA platform beyond genetic medicines into the large obesity market, with combination data suggesting enhanced efficacy over GLP-1 therapy alone.

FAQ

Frequently asked questions about WVE stock

What is the WVE stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Wave Life Sciences, Inc. have a median 12-month price target of $15, with estimates ranging from $10 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WVE stock a buy right now?

Of the 19 analysts covering Wave Life Sciences, Inc., 17 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Wave Life Sciences, Inc. 14 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WVE?

As at 14 Oct 2026, Wave Life Sciences, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (53 of 100).

Will WVE stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +369.3% from the last close, and Ticker Nerd's factor model ranks Wave Life Sciences, Inc. 14 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WVE stock forecast for 2030?

No analyst covering Wave Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WVE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $42 over the next 12 months.

How has WVE stock performed over the past year?

Wave Life Sciences, Inc. returned -60.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Wave Life Sciences, Inc. do?

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health.

What is the latest news on WVE?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference". Wave Life Sciences announced that CEO Paul Bolno is scheduled to participate in a panel on next-generation RNA therapeutics at Chardan’s 10th Annual Healthcare Conference. The panel is scheduled for October 20, 2026, at 9:45 a.m. ET in New York City.

Company

About Wave Life Sciences, Inc.

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.

CEO Dr. Paul B. Bolno M.B.A., M.D. · 317 employees · United States · https://wavelifesciences.com